Exact Sciences was officially delisted from the Nasdaq stock market now that it’s a wholly owned subsidiary of Abbott, with its last day of official trading being last Friday, March 20.
This transaction is expected to add approximately $3 billion of incremental sales in 2026, accelerate Abbott’s 2026 sales growth by approximately 0.5% and dilute 2026 adjusted earnings per share by approximately $0.20.
Exact Sciences is a leader in cancer screening, precision oncology and genetic testing, helping to detect cancer earlier, guide treatment decisions and monitor recurrence.
Cancer screening and precision oncology diagnostics in the U.S. is a $60 billion business.
Exact Sciences is known for product offerings like the Cologuard test, a market-leading noninvasive colorectal cancer screening option.
